AI Verdict
RPRX has stronger fundamentals based on our AI analysis.
RSCF vs RPRX Fundamental Comparison
| Metric | RSCF | RPRX |
|---|---|---|
| Revenue | $1.5M | $2.4B |
| Net Income | $186,946.0 | $770.9M |
| Net Margin | 12.2% | 32.4% |
| ROE | 9.0% | 7.9% |
| ROA | 8.0% | 3.9% |
| Current Ratio | 15.03x | 2.40x |
| Debt/Equity | 0.00x | 0.92x |
| EPS | $0.00 | $1.78 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RSCF vs RPRX: Frequently Asked Questions
Is RSCF or RPRX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RPRX has stronger fundamentals. RSCF is rated SELL (60% confidence) while RPRX is rated HOLD (75% confidence). This is not investment advice.
How does RSCF compare to RPRX fundamentally?
REFLECT SCIENTIFIC, INC. has ROE of 9.0% vs Royalty Pharma plc's 7.9%. Net margins are 12.2% vs 32.4% respectively.
Which stock pays higher dividends, RSCF or RPRX?
RSCF has a dividend yield of N/A or no dividend while RPRX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RSCF or RPRX for long term?
For long-term investing, consider that RSCF has SELL rating with 60% confidence, while RPRX has HOLD rating with 75% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RSCF vs RPRX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RSCF vs RPRX, the AI consensus favors RPRX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.